123 related articles for article (PubMed ID: 37843030)
1. Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells.
Booth L; Roberts JL; Poklepovic A; Dent P
Anticancer Drugs; 2024 Feb; 35(2):177-182. PubMed ID: 37843030
[TBL] [Abstract][Full Text] [Related]
2. The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib.
Booth LA; Roberts JL; Dent P
Semin Cancer Biol; 2020 Nov; 66():129-139. PubMed ID: 31644944
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells.
Rodríguez-Hernández MA; González R; de la Rosa ÁJ; Gallego P; Ordóñez R; Navarro-Villarán E; Contreras L; Rodríguez-Arribas M; González-Gallego J; Álamo-Martínez JM; Marín-Gómez LM; Del Campo JA; Quiles JL; Fuentes JM; de la Cruz J; Mauriz JL; Padillo FJ; Muntané J
J Cell Physiol; 2018 Jan; 234(1):692-708. PubMed ID: 30132846
[TBL] [Abstract][Full Text] [Related]
4. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
5. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
Dent P; Booth L; Poklepovic A; Kirkwood JM
Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
[TBL] [Abstract][Full Text] [Related]
6. Neratinib augments the lethality of [regorafenib + sildenafil].
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
[TBL] [Abstract][Full Text] [Related]
7. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
8. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
9. Nexavar/Stivarga and viagra interact to kill tumor cells.
Tavallai M; Hamed HA; Roberts JL; Cruickshanks N; Chuckalovcak J; Poklepovic A; Booth L; Dent P
J Cell Physiol; 2015 Sep; 230(9):2281-98. PubMed ID: 25704960
[TBL] [Abstract][Full Text] [Related]
10. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of autophagy and cell viability by ceramide species.
Cruickshanks N; Roberts JL; Bareford MD; Tavallai M; Poklepovic A; Booth L; Spiegel S; Dent P
Cancer Biol Ther; 2015; 16(5):733-42. PubMed ID: 25803131
[TBL] [Abstract][Full Text] [Related]
12. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.
Dent P; Booth L; Poklepovic A
Immunometabolism; 2020; 2(1):. PubMed ID: 31885880
[TBL] [Abstract][Full Text] [Related]
14. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Bareford MD; Hamed HA; Tang Y; Cruickshanks N; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
Autophagy; 2011 Oct; 7(10):1261-2. PubMed ID: 21814046
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Bareford MD; Park MA; Yacoub A; Hamed HA; Tang Y; Cruickshanks N; Eulitt P; Hubbard N; Tye G; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
Cancer Res; 2011 Jul; 71(14):4955-67. PubMed ID: 21622715
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
[TBL] [Abstract][Full Text] [Related]
20. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
